Introduction

Prognosis of primary metastatic and metastatic relapse of high-risk (HR) paediatric malignant solid tumours (PMST) is poor. Chemotherapy, radiotherapy and surgery are insufficient for the management of these patient and alternative strategies such as targeted therapy and immunotherapy are needed [1-10]. Although these patients are well candidates for early phase clinical trials, surgical removal of lung or other metastases is often pursued to confirm diagnosis or even achieve a new remission which may prolong survival, particularly in patients with osteosarcoma [5,11,12]. However, the absence of measurable disease after surgery often precludes their inclusion in such trials. In addition, the absence of ongoing paediatric early trials or available slots reduces treatment opportunities for these children. Natural killer (NK) cells are key players of the innate immune system [13]. In haploidentical stem cell transplantation (haplo-SCT), allo-reactive NK cells mediate potent antileukemia effects and preclinical models show that PMST might be also susceptible to NK-cell mediated cytotoxicity [3,14-16]. There are anecdotal reports supporting the role of haplo-SCT in paediatric patients with advanced stage malignant solid tumours [17-22]. Here we present our single centre experience with such approach in 11 children.

Methods

This was a retrospective single centre study of children with primary metastatic and metastatic relapse of HR PMST who underwent haplo-SCT under a compassionate use program. Written informed consent was obtained from parents and all eleven patients were transplanted at our institution. For donor selection, the receptor-ligand mismatch model was the preferred method applied [23]. Donors were mobilized using granulocyte colony-stimulating factor. Conditioning regimen consisted of a combination of methylprednisolone, fludarabine, busulfan and thiotepa in 10 patients, one patient diagnosed with relapsed HR neuroblastoma received therapeutic iodine-131 metaiobenzylguanidine (mIBG) early before conditioning and received melphalan instead of busulphan. Ex vivo graft manipulation included CD3+/CD19+ depletion in 2 patients transplanted before 2013, and αβ+/CD19+ depletion in the remaining 9 patients. Primary graft failure was diagnosed when a patient did not achieve an absolute neutrophils count > 500/µl by day +28. Decline of neutrophil counts bellow 500/µl after previous engraftment was recorded as secondary graft failure. Chimerism was periodically evaluated by PCR analysis in both total mononuclear cells and CD3+ cell subset in peripheral blood. Graft versus host disease (GVHD) prophylaxis consisted of a combination of cyclosporine and methotrexate in 5 patients and mycophenolate in one. Five patients with CD3αβ+ graft cell contents below 25 x 10³/kg received no pharmacological prophylaxis. Standard criteria were applied for the definition and grading of acute and chronic GVHD [24,25]. Serum immunoglobulin levels as well as absolute number of CD3+, CD3+CD4+, CD3+CD8+, CD3-CD56+ and CD20+ cells were evaluated every 30 days after engraftment. Overall survival (OS) was defined as the time form primary diagnosis to death from any cause or last contact and the probability of OS was calculated according to the Kaplan-Meier method. The log-rank test was used to compare the difference in OS with and historical control group of 24 patients with relapsed Ewing`s sarcoma (n=8), osteosarcoma (n=10) and HR neuroblastoma (n=6).

Results

From November 2010 to May 2021 eleven patients with PMST underwent haplo-SCT. Median ages at primary diagnosis and at haplo-SCT were 13 years [1-15] and 14 years [3-17], respectively. Clinical characteristics of these patients are described in Table 1. Three patients were diagnosed with localized (limb) Ewing’s sarcoma (ES) and receive a combination of vincristine, ifosfamide, doxorubicin and etoposide (VIDE), followed by surgical resection of the primary tumour before metastatic relapse as solitary lung metastasis in two (13 and 27 months after primary diagnosis), and as multiple skull metastases in one (36 months after diagnosis). Treatment after relapse and before haplo-SCT included surgical resection of lung metastasis or radiotherapy for skull metastasis, followed by a combination of topotecan plus cyclophosphamide in two, and high-dose ifosfamide followed by myeloablative therapy (MAT) with busulfan plus melphalan (BUMEL) and autologous stem cell rescue in one. Three patients were diagnosed with primary metastatic (lung metastasis in two and multiple bone in one) pelvic ES and received VIDE followed by MAT (BUMEL) and radiotherapy to achieve remission before haplo-SCT; one progressed during VIDE and received radiotherapy, a combination of topotecan plus cyclophosphamide followed by MAT (carboplatin, etoposide plus melphalan) and achieved a partial remission (PR) before haplo-SCT. One patient with localized osteosarcoma received a combination of methotrexate, doxorubicin, ifosfamide and cisplatin (MDIC) followed by surgical resection of primary tumour, then locally relapsed 22 months after primary diagnosis and had local and metastatic (lung) progression during second line chemotherapy with ifofamide plus etoposide, and achieved a second remission (CR2) after surgical removal of primary tumour and lung metastases. Two patients with primary metastatic (multiple lung nodules) osteosarcoma underwent upfront surgical removal of lung metastasis followed by MDIC chemotherapy and local surgery before haplo-SCT.

Two patients with MYCN-amplified HR neuroblastoma received neoadjuvant chemotherapy with vincristine, carboplatin, cisplatin, cyclophosphamide and etoposide (COJEC) followed by a combination of topotecan plus vincristine and doxorubicin (TVD) and MAT (BUMEL), surgical removal of primary tumour and local radiotherapy. One progressed during COJEC chemotherapy and received additional chemotherapy with cyclophosphamide plus topotecan before MAT and then therapeutic mIBG and isotretinoine. Both neuroblastoma patients underwent haplo- SCT with active progressive disease (PD). In total, four patients with primarily metastatic disease received haplo-SCT in first CR (CR1), four in CR2 after metastatic relapse, one in PR, and two with PD. For seven patients who relapsed/progressed before haplo- SCT, median time from primary diagnosis to relapse/progression was 13 months [3-36]. Median time from primary diagnosis to haplo-SCT was 19 months [9-50]. One patient was transplanted from her haploidentical brother and the remaining ten from one progenitor. NK alloreactivity was recorded in four patients (2DL3 and 3DL1 missing ligand in two patients each). Details on graft, NK alloreactivity and infused cells are shown in Table 2. Median number of infused CD34+ and NK cells were 8.93 x 10⁶/kg [3.26- 25.21] and 21.99 x 10⁶/kg [2.26-74.37], respectively. Median number of infused CD20+ was 31.22 x 10³/k [0-1,913]. For nine patients who received an αβ+ depleted graft, the median number of infused αβ+ and γδ+ T-cells was 8.95 x 10³/kg [0-355] and 9.04 x 10⁶/kg [0.8-21.06], respectively. Primary graft failure (GF) occurred in 3 patients, two of whom were rescued with a second transplantation from the same haploidentical donor and from an HLA compatible sibling donor, respectively; one patient rejected 2 subsequent haplo-SCT procedures from the same donor and was finally rescued with a fourth CD45RA ex vivo depleted graft from an alternative haploidentical donor (sister) after conditioning with fludarabine, therosulfan and 2 Gy total body irradiation. Secondary GF occurred in one patient who was rescued with a second transplantation from an alternative HLA compatible sister. Median number of infused CD34+ in these four patients was 6.7 x 10⁶/kg [3.36-12] (Table 2 and 3). Non-fatal grade 2-4 acute GVHD was diagnosed in 4 patients after the first haplo-SCT, including one grade 4, and in 2 additional patients after subsequent haplo-SCT. Three patients developed moderate chronic GVHD successfully managed with steroids, extracorporeal photoaphreresis and ruxolitinib. As expected, NK populations recovered rapidly after haplo-SCT followed by CD8+, CD4+ and CD20+ subsets (Table 4) (20,26,27). Non-fatal viral infection complications were frequent (Table 2). Cytomegalovirus (CMV) reactivation without disease occurred in 5 patients. BK virus (BKV) associated haemorrhagic cystitis was diagnosed in 5 patients, one of whom developed BK virus nephropathy after prolonged high plasma titters of BKV. One patient developed Adenovirus (ADV)-related colitis, one was diagnosed with visceral disseminated Varicella Zoster virus infection, and one developed transient human Herpesvirus 6 (HHV6) encephalitis after his fourth haplo-SCT with CD45RA+ depletion. There were no treatment-related deaths. Five patients relapsed 2 to 8 months after HSCT and died of disease. Six patients are alive in remission after a median follow up of 27 months since haplo-SCT [14-126]. Median OS after primary diagnosis of cancer was significantly higher in the group of patients undergoing haplo- SCT when compared with a historical control group of 24 patients with primary metastatic o metastatic relapse of PMST (46 versus 27 months, p = 0.0177) after a median follow up of 35 [12-148] and 26 [8-86] months, respectively (Table 1 and 2; figure 1 and 2).

Table 1: Clinical characteristics of 11 patients with solid tumours who underwent haploidentical stem cell transplantation (haplo-SCT).

Table 2: Details of graft, NK alloreactivity, infused cells and complications of 11 patients with solid tumours who underwent haploidentical stem cell transplantation (haploSCT).

Table3: Management and outcome of subsequent allografts in 4 patients who developed graft failure after haploidentical stem cell transplantations (haplo-SCT).

Table 4: Lymphocyte subsets and serum immunoglobulin immunorecovery after haploidentical stem cell transplantation (SCT).

Table 5: Clinical characteristics of 24 patients with primary metastatic or relapsed Ewing sarcoma (ES), osteosarcoma (OS), or neuroblastoma (NB).

Discussion

NK cells are part of the innate immune system capable to eliminate tumour cells and their role in cancer immune-surveillance is well established [28,29]. There is evidence from preclinical studies that NK cells may mediate antitumor activity against osteosarcoma lung metastases, ES cells were particularly sensitive in vitro to activated and expanded NK cell-mediated cytotoxicity and the administration of expanded NK cells was able to reduce the development of lung metastases of ES in murine models [3,14,16]. Expression of ligands for activating NK-cell receptors in combination with down-regulation of HLA class I molecules on ES tumour cells are probably associated to this particular sensitivity [13,16,20]. NK cells are considered the main effector of tumour cell killing in paediatric patients who receive anti-GD2 monoclonal antibodies [4]. Allogeneic NK cells may scape the inhibition of autologous NK cells provided by self-HLA signals [15,28]. The use of allogeneic NK cells yielded promising results in

children with neuroblastoma and the administration of isolated or pre-activated and/or expanded autologous and allogeneic NK cell infusions is currently under clinical evaluation in haematological malignancies and paediatric solid tumours such as neuroblastoma, ES, osteosarcoma, rhabdomyosarcoma and central nervous system tumours [4,7,28]. Haplo-SCT represents an approach to exploit the ability of NK cells to kill MHC class I defective tumour cells, and has been successfully applied for the treatment of high risk leukaemia [29,30]. In the paediatric setting, many groups adopt the platform of ex vivo T-cell depletion in order to prevent severe GVHD after haplo-SCT [30,31]. Selective depletion of specific cell subpopulations within the graft such as αβ+ T cells allows the administration of large amounts of γδ+ T cells and NK cells, which might protect the recipient from leukaemia relapse and severe infection, and this approach was reported to be effective in patients with haematological malignancies [30-33]. By contrast, the eventual role and benefit of haplo-SCT for the management of PMST has not been explored in depth [26,27].